dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Salas Puig, Xavier |
dc.contributor.author | Quintana Luque, Manuel |
dc.contributor.author | Seijo Raposo, Ivan Manuel |
dc.contributor.author | Santamarina Pérez, Estevo |
dc.contributor.author | Fonseca Hernandez, Elena |
dc.contributor.author | Toledo Argany, Manuel |
dc.contributor.author | Abraira del Fresno, Laura |
dc.date.accessioned | 2022-05-24T06:57:29Z |
dc.date.available | 2022-05-24T06:57:29Z |
dc.date.issued | 2021 |
dc.identifier.citation | Abraira L, Salas-Puig J, Quintana M, Seijo-Raposo IM, Santamarina E, Fonseca E, et al. Overnight switch from levetiracetam to brivaracetam: safety and tolerability. Epilepsy Behav Reports. 2021;16:100504. |
dc.identifier.issn | 2589-9864 |
dc.identifier.uri | https://hdl.handle.net/11351/7571 |
dc.description | Brivaracetam; Epilepsy; Tolerability |
dc.description.abstract | Brivaracetam is a newer antiseizure medication than levetiracetam. It has a more selective action on the synaptic vesicle glycoprotein 2A binding site, and it seems to provide a more favorable neuropsychiatric profile. The aim of this study was to assess the safety and tolerability of an overnight switch from levetiracetam to brivaracetam.
This was a retrospective descriptive study including patients with epilepsy treated with levetiracetam, who switched due to inefficacy or previous adverse events (AEs). In total, forty-one patients were included (mean age 40.9 ± 17.8 years, women 48.8%). Focal epilepsy represented 75.6% (n = 31) of patients (structural cause [n = 25], unknown cause [n = 6]). Four patients had idiopathic generalized epilepsy, two had developmental and epileptic encephalopathy and four patients were unclassified. The reason to start brivaracetam was inefficacy in 53.7% (n = 22), AEs in 65.9% (25/27 neuropsychiatric) and both in 19.5% (n = 8). Brivaracetam-related AEs were reported in 24.4%. Neuropsychological AEs associated with the previous use of levetiracetam improved in 76% of patients. Treatment was discontinued in 19.5% patients. Patients’ reported seizure frequency improved, worsened and remained stable in 26.8%, 12.2%, and 61.0% of the cases, respectively.
An overnight switching to brivaracetam is safe and well tolerated. This treatment can improve levetiracetam-related neuropsychiatric AEs. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Epilepsy & Behavior Reports;16 |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Anticonvulsius - Ús terapèutic |
dc.subject | Epilèpsia - Tractament |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Anticonvulsants |
dc.subject.mesh | /administration & dosage |
dc.subject.mesh | Treatment Outcome |
dc.subject.mesh | Epilepsy |
dc.title | Overnight switch from levetiracetam to brivaracetam: safety and tolerability |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.ebr.2021.100504 |
dc.subject.decs | anticonvulsivantes |
dc.subject.decs | /administración & dosificación |
dc.subject.decs | resultado del tratamiento |
dc.subject.decs | epilepsia |
dc.relation.publishversion | https://doi.org/10.1016/j.ebr.2021.100504 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | Unitat d’Epilèpsia, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34901817 |
dc.identifier.wos | 000730415800003 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |